Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi(R) in Patients with Advanced Melanoma
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi(R) in Patients with Advanced Melanoma GlobeNewswire July 14, 2025 61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor […]